HOOKIPA Pharma (HOOK) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

HOOK HOOKIPA Pharma

Watchlist

2.320
+0.035+1.53%

Close Nov 26 16:00 ET

2.250
-0.070-3.02%

Post 20:05 ET

22.96MMarket Cap-632P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Hookipa Pharma Price Target Lowered to $7 From $24 at JMP Securities
Yahoo FinanceNov 22 06:51 ET
Sector Update: Health Care Stocks Climb Thursday Afternoon
MT NewswiresNov 21 13:50 ET
HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program
MT NewswiresNov 21 07:42 ET
HOOKIPA Pharma Price Target Cut to $7.00/Share From $24.00 by JMP Securities
Dow JonesNov 21 07:38 ET · Ratings
Hookipa Pharma Announces Workforce Reduction of 80%, Pause of Eseba-vec Program
TipRanksNov 21 06:35 ET
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Cuts Target Price to $7
Moomoo NewsNov 21 00:32 ET · Ratings

Comments

102270433

Nov 25 07:28

$HOOKIPA Pharma (HOOK.US)$
With Gilead Science holding 15% share, it is worthwhile to hold long...

Trytosaveabit

Nov 11 12:09

Watching!

$HOOKIPA Pharma (HOOK.US)$ Watching for news out of the presentation at SITC 2024 from Saturday!

Jaguar8

Oct 31 08:21

NEWS

$HOOKIPA Pharma (HOOK.US)$
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Cent...

Trytosaveabit

Oct 30 06:32

Update

$HOOKIPA Pharma (HOOK.US)$ Reuters· 2 mins ago
HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Trytosaveabit

Sep 24 06:48

Watching! Look at date/time!

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

HOOK HOOKIPA Pharma

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target